NEWS
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
Virios Therapeutics (Nasdaq: VIRI) announced the completion of enrollment in a Phase 2 Long-COVID study for IMC-2, conducted by Bateman Horne Center. The study evaluates the combination of valacyclovir and celecoxib as a treatment for Long-COVID symptoms. Top line results are expected in October 2024.
The randomized, double-blind, placebo-controlled study follows a positive prior proof of concept study showing improvements in fatigue, pain, and other symptoms. Virios believes that activated herpes viruses may trigger or maintain Long-COVID and fibromyalgia. With an estimated 45 million potential adult patients affected by Long-COVID in the U.S., and no FDA-approved treatments available, Virios' antiviral combination could be a significant breakthrough.
The randomized, double-blind, placebo-controlled study follows a positive prior proof of concept study showing improvements in fatigue, pain, and other symptoms. Virios believes that activated herpes viruses may trigger or maintain Long-COVID and fibromyalgia. With an estimated 45 million potential adult patients affected by Long-COVID in the U.S., and no FDA-approved treatments available, Virios' antiviral combination could be a significant breakthrough.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment